Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Hematopoiesis News
Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.
A Pax3 Lineage Gives Rise to Transient Hematopoietic Progenitors
[Development] Investigators showed that the mouse fetal liver and fetal circulation contained a transient population of Pax3 lineage cells with hallmarks of hematopoietic progenitors and the potential to generate both myeloid and erythroid cells.
BRAF Inhibitors Enhance Erythropoiesis and Treat Anemia Through Paradoxical Activation of MAPK Signaling
[Signal Transduction and Targeted Therapy] The authors devised a screening system using primary human hematopoietic stem and progenitor cells. They discovered that BRAF inhibitors, commonly used to treat BRAFV600E melanoma, could effectively promote progenitor cell proliferation by temporarily delaying erythroid differentiation.
IKZF1 Gene Deletions Drive Resistance to Cytarabine in B Cell Precursor Acute Lymphoblastic Leukemia
[Haematologica] The authors modeled loss of IKZF1 function in B cell precursor acute lymphoblastic leukemia (BCP-ALL) cell lines and patient-derived xenografts and compared cellular responses to various chemotherapeutic agents used in the treatment of BCP-ALL.
Azacitidine as Epigenetic Priming for Chemotherapy Is Safe and Well-Tolerated in Infants with Newly Diagnosed KMT2A-Rearranged Acute Lymphoblastic Leukemia: Children’s Oncology Group Trial AALL15P1
[Haematologica] The Children’s Oncology Group trial AALL15P1 tested the safety and tolerability of five days of azacitidine treatment immediately prior to the start of chemotherapy on day six, in four post-induction chemotherapy courses for infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia.
Safety and Efficacy of Flumatinib as Later-Line Therapy in Patients with Chronic Myeloid Leukemia
[Haematologica] The aim of this study was to evaluate the efficacy and safety of flumatinib in later-line treatment of Chinese patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia previously treated with tyrosine kinase inhibitors.
Outcomes with Loncastuximab Tesirine Following CAR T-Cell Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
[Blood Cancer Journal] In this retrospective study, investigators included adults with relapsed or refractory diffuse large B-cell lymphoma who received loncastuximab tesirine monotherapy as third or fourth line treatment after progressing on second line or third line chimeric antigen receptor T-cell therapy (CAR-T), respectively.
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
[Journal of Clinical Oncology] Investigators conducted a randomized, double-blind, placebo-controlled, Phase III trial with 363 patients with asymptomatic, treatment-naïve, Binet stage A chronic lymphocytic leukemia at increased risk of progression to receive ibrutinib at a daily dose of 420 mg or placebo.
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
[New England Journal of Medicine] Researchers conducted a Phase Ib–II multicenter study of obecabtagene (obe-cel) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Obe-cel resulted in a high incidence of durable response among adults with relapsed or refractory B-cell ALL.
Beclin 1 Prevents ISG15-Mediated Cytokine Storms to Secure Fetal Hematopoiesis and Survival
[Journal of Clinical Investigation] Conditional loss of Beclin 1 (Becn1) caused sequential dysfunction and exhaustion of fetal liver hematopoietic stem cells, leading to lethal inflammatory cell-biased hematopoiesis in the fetus.
Lenalidomide-Induced Pure Red Cell Aplasia Is Associated with Elevated Expression of MHC-I Molecules on Erythrocytes
[Nature Communications] A multiple myeloma patient developed pure red cell aplasia (PRCA) following RVd treatment, despite the absence of common PRCA triggers. In vitro analyses revealed lenalidomide as a pivotal disruptor of erythropoiesis.
RSK1 Dependency in FLT3-ITD Acute Myeloid Leukemia
[Blood Cancer Journal] The authors identified ribosomal protein s6 kinase a1 (RSK1) as a core dependency in fms-like tyrosine kinase 3 (FLT3)-internal tandem duplications (ITD) AML and unveiled the existence of crucial bi-directional regulation.
Single-Cell Multiomics Analysis Reveals Dynamic Clonal Evolution and Targetable Phenotypes in Acute Myeloid Leukemia with Complex Karyotype
[Nature Genetics] Researchers combined structural variant discovery and nucleosome occupancy profiling with transcriptomic and immunophenotypic changes in single cells to study intratumoral heterogeneity in complex karyotype AML.
Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.
